Document is current
Any future updates will be listed below
-
Authors
Proietti, Riccardo
Palazzolo, Michael Gerard
Ruff, Christian T.
Lip, Gregory Y. H.
Giugliano, Robert P.
- License Information
-
More Information
Article History
Received: 16 August 2024
Revised: 16 December 2024
Accepted: 21 December 2024
First Online: 19 February 2025
Compliance with ethical standards
:
: Dr. Giugliano is a member of the TIMI Study Group of the Brigham and Women’s Hospital, which has received research grant support to support clinical trials from Anthos Therapeutics, Daiichi Sankyo; and has received honoraria for CME programme, lectures and/or consulting from Artivion, Daiichi Sankyo, Medical Education Resources, Menarini, PhaseBio, SAJA Pharmaceutics, Samsung, Sanofi Aventis, Servier, and Summeet. MGP, CTR, and RPG are members of the TIMI Study Group, which has received institutional research grant support through Brigham and Women’s Hospital from Abbott, Abiomed Inc, Amgen, Anthos Therapeutics, ARCA Biopharma Inc, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo, Ionis Pharmaceuticals Inc, Janssen Research and Development LLC, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals Inc, Roche, Saghmos Therapeutics Inc, Softcell Medical Limited, The Medicines Company, Verve Therapeutics Inc, and Zora Biosciences RP and GYHL have no disclosure of interest.
: The ENGAGE AF-TIMI 48 trail was approved by all relevant institutional review boards and all patients provided informed consent. Pre-registered clinical trial number The pre-registered clinical trial number is NCT00781391.
